Login to Your Account



Aastrom Terminates CLI Trial; Restructures, Shifts to DCM

By Catherine Shaffer
Staff Writer

Wednesday, March 27, 2013
Aastrom Biosciences Inc., of Ann Arbor, Mich., made a wrenching decision to terminate its Phase III REVIVE trial in critical limb ischemia (CLI) and shift its focus to dilated cardiomyopathy (DCM). Management cited challenges in enrolling patients for REVIVE and difficulty finding a partner in a reasonable time frame to improve the situation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription